Press Releases

Receive E-mail Alerts
3 June 2019 at 7:00 AM EDT
Summary ToggleProQR to Present at the JMP Securities Life Sciences Conference
LEIDEN, the Netherlands and CAMBRIDGE, Mass. , June 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the company
15 May 2019 at 7:00 AM EDT
Summary ToggleProQR to Present at the RBC Capital Markets Healthcare Conference
LEIDEN, the Netherlands and CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.  (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that management will
8 May 2019 at 7:00 AM EDT
Summary ToggleProQR Announces Financial Results for the First Quarter of 2019
LEIDEN, Netherlands & CAMBRIDGE, Mass. , May 08, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today reported its financial results for the
22 April 2019 at 7:00 AM EDT
Summary ToggleProQR to Present at Three Scientific Conferences in April
LEIDEN, Netherlands and CAMBRIDGE, Mass. , April 22, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced upcoming presentations
18 April 2019 at 7:00 AM EDT
Summary ToggleProQR Announces Annual Meeting of Shareholders
LEIDEN, Netherlands and CAMBRIDGE, Mass. , April 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the Annual General
18 April 2019 at 7:00 AM EDT
Summary ToggleProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board
LEIDEN, Netherlands & CAMBRIDGE, Mass. , April 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, has nominated Bart Filius , Chief
15 April 2019 at 7:00 AM EDT
Summary ToggleProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10
LEIDEN, The Netherlands and CAMBRIDGE, Mass. , April 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient
1 April 2019 at 7:00 AM EDT
Summary ToggleProQR to Present at the H.C. Wainwright Global Life Sciences Conference
LEIDEN, Netherlands and CAMBRIDGE, Mass. , April 01, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that management will
26 March 2019 at 4:01 PM EDT
Summary ToggleProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
LEIDEN, Netherlands and CAMBRIDGE, Mass. , March 26, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the strategic spin out
11 March 2019 at 4:00 AM EDT
Summary ToggleProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
LEIDEN, Netherlands and CAMBRIDGE, Mass. , March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed
5 March 2019 at 7:00 AM EST
Summary ToggleProQR to Present at Cowen Health Care Conference
LEIDEN, Netherlands and CAMBRIDGE, Mass. , March 05, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the management will
27 February 2019 at 7:00 AM EST
Summary ToggleProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
LEIDEN, The Netherlands & CAMBRIDGE, Mass. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today reported its financial results
29 January 2019 at 8:30 AM EST
Summary ToggleProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
LEIDEN, the Netherlands & CAMBRIDGE, Mass. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines, today announced its “ProQR Vision 2023” strategy, which is focused on the development and
7 January 2019 at 7:00 AM EST
Summary ToggleProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it has reached
3 January 2019 at 7:00 AM EST
Summary ToggleProQR to Host R&D Day in New York on January 29
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) will host a Research & Development Day for investors on Tuesday, January 29 at 8:00 am ET at the Lotte New York Palace Hotel in New York, NY .
2 January 2019 at 7:00 AM EST
Summary ToggleProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it received Fast Track